- Home
- JANX vs SDGR Comparison
JANX vs SDGR Comparison
Compare JANX & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- SDGR
- Stock Information
- Founded
- JANX 2017
- SDGR 1990
- Country
- JANX United States
- SDGR United States
- Employees
- JANX N/A
- SDGR N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- JANX Health Care
- SDGR Health Care
- Exchange
- JANX Nasdaq
- SDGR Nasdaq
- Market Cap
- JANX 1.4B
- SDGR 1.7B
- IPO Year
- JANX 2021
- SDGR 2020
- Fundamental
- Price
- JANX $24.87
- SDGR $18.47
- Analyst Decision
- JANX Strong Buy
- SDGR Buy
- Analyst Count
- JANX 8
- SDGR 6
- Target Price
- JANX $90.63
- SDGR $31.67
- AVG Volume (30 Days)
- JANX 892.8K
- SDGR 1.3M
- Earning Date
- JANX 08-07-2025
- SDGR 08-06-2025
- Dividend Yield
- JANX N/A
- SDGR N/A
- EPS Growth
- JANX N/A
- SDGR N/A
- EPS
- JANX N/A
- SDGR N/A
- Revenue
- JANX $439,000.00
- SDGR $237,917,000.00
- Revenue This Year
- JANX N/A
- SDGR $24.44
- Revenue Next Year
- JANX $1,470.83
- SDGR $22.17
- P/E Ratio
- JANX N/A
- SDGR N/A
- Revenue Growth
- JANX N/A
- SDGR 18.59
- 52 Week Low
- JANX $21.97
- SDGR $16.60
- 52 Week High
- JANX $71.71
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- JANX 51.13
- SDGR 38.90
- Support Level
- JANX $23.96
- SDGR $17.00
- Resistance Level
- JANX $25.93
- SDGR $19.91
- Average True Range (ATR)
- JANX 1.55
- SDGR 1.02
- MACD
- JANX 0.06
- SDGR -0.09
- Stochastic Oscillator
- JANX 61.91
- SDGR 37.04
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.